Xtandi 40 MG capsule 120S
Ended Awarded
- Contract number
- SPE2DB26FX1LE
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $50,035
Award facts
- Contract value 100% obligated
- $50,035.08 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency has awarded a firm fixed-price delivery order valued at $50,035.08 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). The award was issued on November 6, 2025, with an ultimate completion date of November 7, 2025, and carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's recently established single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency, designated as contract SPE2DR under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative.
DMS Pharmaceutical Group's PPV-G GEN V contract, awarded on November 13, 2025, carries a ceiling value of $499,999,999 and extends through December 31, 2036, positioning the company as a regional prime vendor contractor within the broader $30.3 billion PPV-G GEN V acquisition strategy. The IDC authorizes the Defense Logistics Agency to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support military healthcare facilities worldwide. DMS Pharmaceutical Group's established performance on numerous delivery orders for specialized pharmaceuticals, including oncology treatments and specialty medications, demonstrates its capability to fulfill the diverse pharmaceutical requirements of the Department of Defense medical system.
Quick answers
Who was awarded contract SPE2DB26FX1LE?
SPE2DB26FX1LE was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 6, 2025.
How much is contract SPE2DB26FX1LE worth?
The government has obligated $50,035 on SPE2DB26FX1LE.
Is contract SPE2DB26FX1LE an order under another contract?
Yes. SPE2DB26FX1LE is a delivery order under SPE2DB22D9353, an indefinite delivery contract.
Was contract SPE2DB26FX1LE competed?
The extent of competition for SPE2DB26FX1LE was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award